Milvexian Granted U.S. FDA Fast Track Designation for All Th

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients,... | May 25, 2023

Related Keywords

Bristol Myers Squibb , Bristol Myers Squibb Janssen , Arthurl Bloomfield , Johnson Janssen , Robert Harrington , Xia Fxia , Puneet Mohan , Facebook , Instagram , Global Program , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , Youtube , Exchange Commission , Stanford University , Janssen Pharmaceuticals Inc , Librexia Program , Linkedin , Department Of Medicine , Twitter , Janssen Pharmaceuticals , Janssen Pharmaceutical Companies , Fast Track Designation , Track Designation , Global Program Lead , Bristol Myers , Myers Squibb , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Bristol Myers Squibb Company Stock Exchange , News , Information , Press Release , The , Ibrexia , Program , Valuating , Ilvexian , Us , Unrivaled , Most , Comprehensive , Factor , Cia , Inhibitor , Linical , Development , O , Gate , End , Hill , Rovide , Xtensive , Data , Rom , Early Bmy Us1101221083 ,